Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COMPUGROUP MEDICAL SOCIETAS EUROPAEA

(COP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CompuGroup Medical SE: Release of a capital market information

09/17/2019 | 12:30pm EDT

DGAP Post-admission Duties announcement: CompuGroup Medical SE / Share Buyback
CompuGroup Medical SE: Release of a capital market information

17.09.2019 / 18:29
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


CompuGroup Medical SE: Disclosure Pursuant to Article 2 Para. 1 of the Commission Delegated Regulation (EU) No 2016/1052 supplementing Regulation (EU) No 596/2014 (MAR) / Purchase of Treasury Shares

Disclosure Pursuant to Article 2 Para. 1 of the Commission Delegated Regulation (EU) No 2016/1052 supplementing Regulation (EU) No 596/2014 (MAR) / Purchase of Treasury Shares

The share buyback announced by CompuGroup Medical SE by way of the ad hoc notification of September 17, 2019, will be conducted starting on September 18, 2019. Over a time period until at the latest March 31, 2020, up to 930,825 treasury shares of the Company shall be repurchased, corresponding to a portion of the current nominal share capital of approximately 1.75%, subject to an overall purchase volume limit of EUR 48,400,000.00 (excluding ancillary costs of purchase). The share buyback shall be carried out exclusively via the stock exchange in electronic trading through the Frankfurt Stock Exchange (Xetra). While the repurchased shares may be used for all purposes covered by the authorization granted by the general meeting of May 15, 2019, CompuGroup Medical SE intends to redeem the major part of the repurchased shares or use them for potential acquisitions.

The share buyback will be conducted pursuant to the Safe-Harbour-Rules of Article 5 of the Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014 (Market Abuse Regulation), in conjunction with the Delegated Regulation (EU) 2016/1052 of the Commission of March 8, 2016 (Del.-Reg.).

The share buyback will be carried out by a credit institute. The credit institute will decide independently of the Company when to repurchase the shares and on each occasion how many shares to acquire, without the Company having any influence over these decisions (Art. 4 para. 2 lit. b) Del.-Reg.). The Company's right to early termination of the mandate for the credit institute and/or to transfer the mandate to another or several other credit institutes shall remain unaffected.

The share buyback program may be suspended and resumed at any time in compliance with all applicable statutory provisions.

Pursuant to the authorization granted by the general meeting of May 15, 2019, the purchase price per share to be paid by the Company must not exceed, or fall short of, the volume-weighted average stock exchange price of the Company's shares in Xetra trading at the Frankfurt Stock Exchange (or any functionally comparable successor system replacing the Xetra system) on the last five trading days before the day of purchase, by more than 10%. In addition, the conducting credit institute has undertaken vis-à-vis the Company, amongst others, to observe all trading restrictions pursuant to Art. 3 Del.-Reg. Inter alia, pursuant to Art. 3 para. 2 Del.-Reg., no purchase price may be paid which exceeds the price of the last independent trade or the highest independent bid placed at the time of the purchase on the stock exchange on which the purchase is carried out, whichever value is the highest. Further, pursuant to Art. 3 para. 3 Del.-Reg., no more than 25% of the average daily volume of shares on the stock exchange on which the purchase is carried out may be acquired.

Information on the transactions relating to the share buyback will be adequately publicly disclosed pursuant to the requirements of Art. 2 para. 3 sent. 1 in conjunction with para. 2 Del.-Reg. no later than on the seventh trading day after their execution. Furthermore, CompuGroup Medical SE will publish the transactions disclosed on its website www.cgm.com in the Investor Relations section and ensure that the information will be publicly accessible for a period of at least five years from the day of adequate disclosure (Art. 2 para. 3 sent. 2 Del.-Reg.).

Koblenz, September 17, 2019

The Management Board

CompuGroup Medical SE
Investor Relations
Maria Trost 21
56070 Koblenz, Germany
T: 49 (0) 261 8000-6200
 



17.09.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CompuGroup Medical SE
Maria Trost 21
56070 Koblenz
Germany
Internet: www.cgm.com

 
End of News DGAP News Service

875095  17.09.2019 

fncls.ssp?fn=show_t_gif&application_id=875095&application_name=news&site_id=zonebourse

ę EQS 2019
All news about COMPUGROUP MEDICAL SOCIETAS EUROPAEA
09/21COMPUGROUP MEDICAL SE & CO. KGAA : Preliminary announcement of the publication of quarterl..
EQ
09/20COMPUGROUP MEDICAL : Deutsche Bank remains its Buy rating
MD
09/16COMPUGROUP MEDICAL : Warburg Research revises his opinion and turns to Neutral
MD
09/15COMPUGROUP MEDICAL : Receives a Sell rating from Baader Bank
MD
09/15COMPUGROUP MEDICAL : Receives a Buy rating from Warburg Research
MD
09/15COMPUGROUP MEDICAL : Gets a Sell rating from Baader Bank
MD
09/14COMPUGROUP MEDICAL : Receives a Buy rating from Jefferies
MD
09/14COMPUGROUP MEDICAL : áMedicaláannounces medium-termátargets foráEBITDA-margináfor the firs..
PU
09/14COMPUGROUP MEDICAL : announces medium-term targets for EBITDA-margin for the first time an..
EQ
09/14PRESS RELEASE : CompuGroup Medical announces medium-term targets for EBITDA-margin for the..
DJ
More news
Analyst Recommendations on COMPUGROUP MEDICAL SOCIETAS EUROPAEA
More recommendations
Financials
Sales 2021 1 022 M 1 198 M 1 198 M
Net income 2021 81,8 M 95,9 M 95,9 M
Net Debt 2021 504 M 590 M 590 M
P/E ratio 2021 49,7x
Yield 2021 0,75%
Capitalization 3 989 M 4 671 M 4 676 M
EV / Sales 2021 4,40x
EV / Sales 2022 4,08x
Nbr of Employees 8 030
Free-Float 48,8%
Chart COMPUGROUP MEDICAL SOCIETAS EUROPAEA
Duration : Period :
CompuGroup Medical Societas Europaea Technical Analysis Chart | COP | DE0005437305 | MarketScreener
Technical analysis trends COMPUGROUP MEDICAL SOCIETAS EUROPAEA
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 75,65 €
Average target price 84,30 €
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Dirk W÷ssner Chairman-Management Board & CEO
Michael Rauch Chief Financial Officer
Philipp von Ilberg Chairman-Supervisory Board
Frank Brecher Chief Technology Officer
Sven Thomas MŘller Vice Chairman & Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
COMPUGROUP MEDICAL SOCIETAS EUROPAEA-3.75%4 671
ORACLE CORPORATION38.23%245 868
SAP SE13.08%167 462
INTUIT INC.52.00%157 825
SERVICENOW, INC.21.05%132 019
DOCUSIGN, INC.22.52%53 580